CVS Health (NYSE:CVS) Price Target Raised to $115.00

CVS Health (NYSE:CVS) had its target price boosted by stock analysts at UBS Group from $100.00 to $115.00 in a research report issued on Monday,MarketScreener reports. The brokerage currently has a “buy” rating on the pharmacy operator’s stock. UBS Group’s price objective points to a potential upside of 20.23% from the company’s previous close.

Several other brokerages also recently weighed in on CVS. TD Cowen increased their price target on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Robert W. Baird upped their price objective on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Mizuho lifted their target price on CVS Health from $102.00 to $110.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 20th. Royal Bank Of Canada boosted their target price on shares of CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Finally, Barclays raised their price target on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.68.

CVS Health Trading Down 0.3%

Shares of CVS Health stock traded down $0.28 during trading on Monday, hitting $95.65. The stock had a trading volume of 301,488 shares, compared to its average volume of 8,484,257. CVS Health has a 12 month low of $58.50 and a 12 month high of $98.43. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm’s fifty day simple moving average is $84.13 and its 200-day simple moving average is $80.04. The stock has a market cap of $122.05 billion, a PE ratio of 42.16, a PEG ratio of 0.94 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts expect that CVS Health will post 7.44 EPS for the current fiscal year.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Insiders own 0.85% of the company’s stock.

Institutional Trading of CVS Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kingsview Wealth Management LLC grew its position in CVS Health by 316.2% during the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock worth $7,873,000 after buying an additional 79,340 shares during the period. Assetmark Inc. lifted its position in shares of CVS Health by 12.5% during the 3rd quarter. Assetmark Inc. now owns 678,558 shares of the pharmacy operator’s stock valued at $51,156,000 after acquiring an additional 75,603 shares during the period. Intech Investment Management LLC boosted its stake in shares of CVS Health by 50.3% during the 3rd quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock worth $6,526,000 after acquiring an additional 28,953 shares in the last quarter. Hamlin Capital Management LLC acquired a new stake in shares of CVS Health in the 4th quarter worth approximately $160,844,000. Finally, Cresset Asset Management LLC increased its stake in CVS Health by 56.8% in the 3rd quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock valued at $2,675,000 after purchasing an additional 12,849 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.